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Equine herpesvirus type 1 (EHV-1) is the causative agent of equine herpes myeloencephalopathy,
of which outbreaks are reported with increasing frequency throughout North America and Europe.
This has resulted in its classification as a potentially emerging disease by the US Department of
Agriculture. Recently, it was found that a single nucleotide polymorphism (SNP) in the viral DNA
polymerase gene (ORF30) at aa 752 (NAD) is associated with the neurovirulent potential of
EHV-1. In the present study, equine respiratory mucosal explants were inoculated with several
Belgian isolates typed in their ORF30 as D752 or N752, to evaluate a possible difference in
replication in the upper respiratory tract. In addition, to evaluate whether any observed differences
could be attributed to the SNP associated with neurovirulence, the experiments were repeated
with parental Ab4 (reference neurovirulent strain), parental NY03 (reference non-neurovirulent
strain) and their N/D revertant recombinant viruses. The salient findings were that EHV-1 spreads
plaquewise in the epithelium, but plaques never cross the basement membrane (BM). However,
single EHV-1-infected cells could be observed below the BM at 36 h post-inoculation (p.i.) for all
N752 isolates and at 24 h p.i. for all D752 isolates, and were identified as monocytic cells and T
lymphocytes. Interestingly, the number of infected cells was two to five times higher for D752
isolates compared with N752 isolates at every time point analysed. Finally, this study showed that
equine respiratory explants are a valuable and reproducible model to study EHV-1 neurovirulence
in vitro, thereby reducing the need for horses as experimental animals.
INTRODUCTION
Equine herpesvirus 1 (EHV-1) is a ubiquitous respiratory
viral pathogen that causes serious economic losses in the
horse industry worldwide (Allen & Bryans, 1986; Bryans &
Allen, 1989; Brosnahan & Osterrieder, 2009). EHV-1
exerts its impact by causing respiratory tract disease, but it
can also cause abortion, neonatal foal death and nervous
system disorders (Patel & Heldens, 2005; Lunn et al.,
2009). The mucosa of the upper airway tract is the first line
of defence against respiratory diseases (Timoney, 2004).
It is also the primary replication site of EHV-1, as it is
for most alphaherpesviruses (Kydd et al., 1994a; Van
Maanen, 2002; Van Maanen & Cullinane, 2002; Gryspeerdt
et al., 2010). Subsequently, the virus disseminates via a
leukocyte-associated viraemia, which enables EHV-1 to
reach end-vessel endothelia in the uterus and central
nervous system (Allen & Bryans, 1986; Kydd et al., 1994b).
In these organ systems, virus replication can result in
vasculitis and perivasculitis, ultimately resulting in abor-
tion and myeloencephalopathy, respectively. Devastating
outbreaks of equine herpes myeloencephalopathy are
reported with increasing frequency throughout North
America and Europe (Kohn et al., 2006; Perkins et al.,
2009; Pusterla et al., 2009), resulting in its classification as a
potentially emerging disease by the US Department of
Agriculture’s Animal and Plant Health Inspection Service
(USDA APHIS, 2007).
Recently, it was shown by Nugent et al. (2006) that a single
nucleotide polymorphism (SNP) in the catalytic subunit of
the viral DNA polymerase, encoded by open reading frame3These authors contributed equally to this work.
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(ORF) 30, causing a substitution of asparagine (N) by
aspartic acid (D) at aa 752, is significantly associated with
the neurovirulent potential of naturally occurring strains.
The causal relationship between this SNP in EHV-1
polymerase and neuropathogenicity in the horse was
further confirmed through targeted mutagenesis of this
single nucleotide in the genome of EHV (Goodman et al.,
2007; Van de Walle et al., 2009). Unfortunately, to date,
studies to compare neurovirulent and non-neurovirulent
EHV-1 isolates can only be carried out in its natural host,
the horse. The murine model of EHV-1 infection is a
valuable model to study EHV-1 in vivo (Awan et al., 1990;
Van Woensel et al., 1995; Galosi et al., 2004); however, it
cannot be used to study EHV-1 neuropathogenicity
(Goodman et al., 2007). To compare the growth kinetics
of neurovirulent and non-neurovirulent EHV-1 strains, an
in vitro model of mouse cerebral cortex cells has been
described, but no convincing correlation between the D/N
difference in ORF30 and replication efficiency in murine
neurons has been observed (Yamada et al., 2008).
Consequently, there is a huge need for alternative models
to study EHV-1 neuropathogenicity to minimize the
necessity of using horses as experimental animals.
Previously, we successfully established an in vitro model
of equine respiratory mucosal explants (Vandekerckhove
et al., 2009). Such explant models provide accessible means
to mimic the in vivo situation, as three-dimensional
structure and normal cell–cell contacts are maintained
(Glorieux et al., 2007; Vandekerckhove et al., 2009). Hence,
in vitro equine respiratory mucosal explants might provide
not only a good alternative to reduce the number of in vivo
horse experiments, but also a useful tool to obtain more
detailed information on the invasion mechanisms of
EHV-1 in general and specifically the difference between
neurovirulent and non-neurovirulent isolates.
Therefore, the aim of the present study was to unravel the
invasion mechanisms and kinetics of EHV-1 in the equine
respiratory mucosal explant model. In addition, several
non-neurovirulent (N752) and neurovirulent (D752) EHV-1
isolates were tested in this explant model to evaluate its
potential to discriminate between isolates, evaluate their
effect on leukocytes and ultimately contribute to an
improved characterization of the pathogenesis of EHV-1
neurological disease.
RESULTS
Evaluation of EHV-1 replication in equine
respiratory nasal mucosal explants
Nasal and nasopharyngeal explants of three individual
horses were inoculated with the D752 isolate 03P37, whilst
nasal and nasopharyngeal explants of three other horses
were inoculated with the N752 isolate 97P70. For each
animal, one explant was examined at each collected time
point [0, 12, 24, 36, 48 and 72 h post-inoculation (p.i.)].
For both isolates, single infected cells in the epithelium
were visible at 12 h p.i., which mainly consisted of
epithelial cells, with a rare infected macrophage or CD5+
T lymphocyte (data not shown). For both strains, EHV-1-
induced epithelial plaques were observed from 24 h p.i.
onwards, which increased in both volume and latitude
over time, with a significant increase between 36 and 48 h
p.i. (P,0.0001 for both 03P37 and 97P70, Fig. 1a, b). At
48 and 72 h p.i., a significant difference in plaque volume
was observed between 03P37 and 97P70 (Fig. 1b). In
addition, the number of plaques also increased over time,
especially between 36 and 48 h p.i., but without any
significant difference between the strains (Fig. 1d).
Interestingly, EHV-1-induced plaques did not cross the
basement membrane (BM) at any observed time point
p.i., but individual EHV-1-infected cells in the connective
tissue were observed below the BM (Fig. 1c). Here, a
difference between these two strains was observed when
evaluating the time point of BM crossing of the basement
membrane via single EHV-1-infected cells. For 97P70, a
non-neurovirulent (N752) isolate, individual infected cells
were present below the BM starting from 36 h p.i.
(Fig. 2b). EHV-1-infected cells were present in all
examined regions for both nasal septum and nasophar-
ynx, but were mainly situated below EHV-1-induced
plaques in the epithelium (Fig. 2a, b, regions A and B)
and their number increased over time (Fig. 2b). In
contrast, for 03P37, a neurovirulent (D752) EHV-1 isolate,
individual infected cells below the BM were already
present at 24 h p.i. (Fig. 2b). These results indicated a
difference between the strains regarding the moment
when they are able to cross the BM barrier via single
EHV-1-infected cells, and could suggest a difference in
invasion kinetics between neurovirulent and non-neuro-
virulent strains. Furthermore, a difference in leukocyte
tropism was also observed between both strains. For
97P70, the N752 strain, individual infected cells were
equally identified as CD5+ T lymphocytes and CD172a+
monocytic cells (Table 1). B cells were present, but were
rarely infected (Table 1). EHV-1-infected CD5+ T
lymphocytes were further characterized and consisted
mainly of CD4+ T lymphocytes, but CD8+ T lymphocytes
were also susceptible to infection (Table 1). For 03P37,
the D752 strain, however, the majority of individual
infected cells were CD172a+, and only a small portion of
EHV-1 carrier cells were identified as CD5+ T lympho-
cytes (Table 1). Here also, both T-lymphocyte subpopula-
tions were equally infected with EHV-1, and B
lymphocytes were rarely infected (Table 1).
In conclusion, this experiment indicated a difference in (i)
invasion kinetics (time point of crossing the BM barrier via
single EHV-1-infected cells) and (ii) in cell tropism of the
infected cells, between 97P70 and 03P37. However, as
different horses were used for the inoculation with the two
Belgian isolates, an influence of the donor horse and/or
virus strains on the outcome of the experiment could not
yet be excluded.
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Quantification of epithelial plaques and single
EHV-1-infected cells of different Belgian EHV-1
isolates in respiratory nasal mucosal explants
derived from the same horse
To substantiate our findings, identical experiments were
performed with more Belgian D752 and N752 isolates, and
this time all strains were inoculated on explants derived
from the same horse to exclude any inter-horse variability.
In line with what was observed in the first experiment, no
significant differences were observed in plaque latitude
between the Belgian D752 and N752 isolates (Fig. 3a). A
significant increase was also observed in plaque latitude from
24 to 48 h p.i. for all isolates (P¡0.05, Fig. 3a), with the
exception of the D752 isolate 99P136, where only a slight
increase was observed. For the number of plaques, no
significant differences were observed between the isolates at
24 h p.i. (Fig. 3b). However, at 48 h p.i., significantly more
plaques were observed for the isolates 94P247 and 97P70
carrying the N752 SNP compared with the D752 isolates
(P¡0.05, Fig. 3b). This was in contrast to the first experiment,
where no significant differences in number of plaques were
observed between the D752 isolate 03P37 and the N752 isolate
97P70 at 48 h p.i. An explanation for this discrepancy in
results could be that, in the second experiments, these isolates
were tested on explants from the same horse, in contrast to the
first experiment where different horses were used to evaluate
the two isolates 03P37 and 97P70.
In the first experiment, a difference in invasion kinetics was
observed between these two isolates and similar results
were obtained in our second experiment. At 24 h p.i.,
single infected cells were present in the connective tissue
below the BM barrier for all neurovirulent (D752) isolates,
in striking contrast to the non-neurovirulent N752 isolates
where infection remained limited to the epithelium at that
time point (Table 2). The vast majority of D752-infected
cells belonged to the CD172a+ monocyte lineage (CML)
and some cells were identified as CD5+ T lymphocytes at
that time point (Table 2). Also, isolate 03P37 infected twice
as many immune cells in the lamina propria compared
with all other D752 isolates (data not shown). At 48 h p.i.,
single EHV-1-infected cells were present in the lamina
propria below the BM barrier for all EHV-1 isolates,
irrespective of their genotype (Table 2). In general,
individual infected cells were equally identified as CD5+
T lymphocytes and CD172a+ CML, irrespective of the D/N
genotype (Table 2). The EHV-1-infected CD5+ T lympho-
cytes belonged to CD4+ as well as CD8+ T lymphocytes
(Table 2). In line with what was observed in the first
experiment, and in striking contrast to the other tested
D752 isolates, the most important carrier cells for the
neurovirulent isolate 03P37 were CD172a+ cells, followed
by a smaller portion of infected T lymphocytes (Table 2).
Although no differences were observed in infected cell type
between D752 and N752 isolates, with the exception of
03P37, a clear difference was observed in the number of
single EHV-1-infected cells in the lamina propria between
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Fig. 1. Evolution of plaque formation in the epithelium of nasal
septum explants. Equine respiratory mucosal explants were
inoculated with the Belgian isolate 97P70 (N752; empty bars) or
03P37 (D752; filled bars). As results were identical upon infection
of tissue from nasal septum or from nasopharynx, only data from
the nasal septum are shown. At 0, 12, 24, 36, 48 and 72 h p.i.,
explants were collected and analysed. One hundred consecutive
sections were prepared and several parameters were determined.
All data shown represent means+SD of triplicate independent
experiments, and P values for statistical significance are given for
each strain. Asterisks indicate statistically significant differences
(P¡0.05). (a, b) Plaque latitudes (a) and volumes (b) were
measured for ten plaques at every time point and for each horse.
(c) Representative confocal photomicrographs illustrating the
evolution over time of EHV-1-induced plaques in the nasal
septum (magnification 20). (d) The number of plaques was
determined at 0, 12, 24, 36, 48 and 72 h p.i. For each horse and
isolate, 100 cryosections were analysed at every time point to
count plaques.
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the isolates. It was apparent that neurovirulent D752 isolates
had a greater number of EHV-1-infected cells in the lamina
propria compared with N752 isolates (Fig. 4). Although
these results were similar to what was observed in the first
experiment, they did not reach significance due to
variation between the N752 isolates.
Based on this second experiment including more Belgian
D752 and N752 isolates, we concluded that, for the N752
isolates a higher number of epithelial plaques could be
found, and for the D752 isolates there was a faster migration
through the BM barrier via single EHV-1-infected cells
along with a greater number of single EHV-1-infected cells
below the BM barrier.
The SNP in the EHV-1 polymerase is not
responsible for the observed differences in
epithelial plaque number and immune cell
tropism, but is important for invasion kinetics as
well as infection rate of immune cells
Finally, a third experiment was performed to test the
hypothesis that the D/N SNP in the ORF30 polymerase and
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Fig. 2. Quantification of single EHV-1-
infected cells in different zones of nasal
septum and nasopharynx for a non-neuroviru-
lent (97P70) and a neurovirulent (03P37)
EHV-1 strain. (a) Schematic overview of the
structure of the nasal septum and nasopharynx
with the different analysed regions of interest
as described in Methods. I, Epithelium; II,
connective tissue; III, blood vessel; IV, glands.
(b) One hundred sections of the tissues were
made per time point and the total number of
infected cells per zone and per time point were
determined. The data shown represent
means±SD of triplicate independent experi-
ments. ROI, Region of interest.
Table 1. Percentage of marker-positive EHV-1-infected individual cells at various time points after inoculation with two Belgian
EHV-1 isolates
Time (h
p.i.)
Percentage of marker-positive EHV-1-infected individual cells in 20 cryosections per cell marker
97P70 03P37
CD172a+ CD5+ CD4+ CD8+ IgM+ CD172a+ CD5+ CD4+ CD8+ IgM+
24 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 74.1±7.3 12.5±4.4 14.3±7.4 4.9±1.6 0.0±0.0
36 38.6±21.6 19.7±19.5 37.3±17.2 4.3±3.5 0.0±0.0 70.9±20.0 18.1±16.3 22.8±11.2 12.4±2.4 0.7±1.2
48 26.2±1.3 47.2±11.4 40.5±19.3 24.7±4.8 2.9±1.4 69.4±6.0 11.0±2.0 13.9±3.5 6.4±3.6 0.8±0.3
72 30.4±9.8 53.9±5.9 50.0±21.9 25.1±7.2 1.9±1.3 73.4±12.9 14.3±1.2 13.7±6.3 7.7±3.4 0.9±0.6
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the observed differences between the Belgian D752 and N752
isolates are linked. To this end, explants from the same
horse were inoculated with the non-neurovirulent (N752)
NY03 or neurovirulent (D752) Ab4 reference strain or their
respective D/N recombinant viruses. These viruses are
completely identical in their genomic background with the
exception of the SNP at position 752 in the ORF30 DNA
polymerase.
At both 24 and 48 h p.i., no differences were observed in
plaque latitudes between the D752 and N752 revertant
viruses, but in line with our previous experiments, a
significant increase in plaque latitude was observed
between these two time points p.i. (data not shown). The
differences in plaque numbers at 48 h p.i., as seen
previously between the D752 and N752 Belgian isolates
(Fig. 3), could not be confirmed using the D/N revertant
viruses. No significant differences in the number of plaques
at 48 h p.i. were observed between the D/N recombinant
viruses of either Ab4 (neurovirulent in origin) or NY03
(non-neurovirulent in origin) (Fig. 5a). This indicated that
the differences in plaque numbers could not be attributed
to the D/N SNP.
Despite this, a role for the D/N SNP in invasion kinetics
and number of infected immune cells could be observed.
For parental Ab4, the D752 revertant Ab4 and the D752
mutant NY03 virus strains, all typed as neurovirulent,
single EHV-1-infected cells were present at 24 h p.i. below
the BM, whereas for the parental NY03, the N752 revertant
NY03 and the N752 Ab4 mutant, infected cells were only
present starting from 48 h p.i. (Table 3). Interestingly, the
strains with D752 in the ORF30 region (D752 revertant Ab4
and D752 mutant NY03) showed a significantly greater
number of individual EHV-1-infected cells below the BM
when compared with the N752 strains (Fig. 5b).
A difference in leukocyte tropism between 03P37 (D752)
and 97P70 (N752), two Belgian field isolates, was observed,
but this difference was not apparent using other Belgian D
and N field isolates (Table 2). Therefore, the leukocyte
tropism of Ab4, NY03 and their D/N recombinant viruses
was evaluated to determine whether the D/N SNP in the
catalytic subunit of the viral DNA polymerase could be
responsible for the exceptional behaviour of 03P37 or not.
Using the Ab4 and NY03 recombinant viruses, no
difference in leukocyte tropism was observed and indi-
vidual infected cells were equally identified as CD5+ T
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Fig. 3. Evolution of plaque formation in epithelium of nasal
explants for various Belgian neurovirulent and non-neurovirulent
EHV-1 isolates. Equine respiratory mucosal explants were
inoculated with several Belgian neurovirulent (D752) or non-
neurovirulent (N752) isolates. At 0, 24 and 48 h p.i., explants were
collected, and 100 consecutive sections were made and analysed
to determine plaque latitude (a) and the number of plaques (b).
Empty bars, 24 h p.i.; filled bars, 48 h p.i. All data represent
means+SD of triplicate independent experiments. Asterisks
indicate statistically significant differences (P¡0.05). Data with a
different letter (a or b) are significantly different from one another.
Table 2. Percentage of marker-positive EHV-1-infected individual cells for different Belgian EHV-1 isolates
SNP/isolate Percentage of marker-positive EHV-1-infected individual cells in 20 cryosections per cell marker
24 h p.i. 48 h p.i.
CD172a+ CD5+ CD4+ CD8+ IgM+ CD172a+ CD5+ CD4+ CD8+ IgM+
D752
97P82 86.1±2.4 4.2±7.2 0.0±0.0 0.0±0.0 0.0±0.0 45±1.6 44.8±5.1 31.1±3 15.2±3.2 2.4±1.7
99P136 81.1±20 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 39.9±2.4 51.1±4.1 35.4±19.7 16±9.5 0.0±0.0
03P37 83±2.9 9.9±4.4 0.0±0.0 0.0±0.0 0.0±0.0 65.5±7.4 23.1±7.5 13.1±4.2 11±2.3 1.8±1.8
N752
94P247 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 26.8±4 39.9±1.9 25.8±17.8 17.9±10.5 3.4±0.9
97P70 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 25.8±1.3 50.7±14 43±7.3 28±6.1 0.0±0.0
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lymphocytes and CD172a+ cells at 48 h p.i. (Table 3). In
addition, the infected T lymphocytes consisted of CD4+
and to a lesser extent CD8+ T lymphocytes (Table 3).
With this final experiment, we could show that the D/N
SNP was not responsible for differences in plaque number
or for the tropism of immune cells. However, the D/N SNP
appeared to be responsible for (i) faster invasion kinetics of
D752 strains compared with N752 strains, and (ii) higher
infection rates of infected cells below the BM barrier when
EHV-1 carried the D752 genotype.
DISCUSSION
In general, respiratory alphaherpesviruses start their
pathogenesis in the upper respiratory tract where primary
replication occurs in epithelial cells and results in upper
respiratory tract disease. Hereafter, they invade through the
BM and the underlying lamina propria, where the virus can
reach blood vessels and rapidly disseminate in the body via
a cell-associated viraemia. This enables the virus to reach
secondary target organs where replication can cause severe
symptoms such as abortion and nervous system disorders
(Sabo et al., 1969; Wyler et al., 1989; Gibson et al., 1992).
Recently, Glorieux et al. (2007) studied the replication and
invasion strategies of pseudorabies virus (PRV; suid
herpesvirus 1), a porcine alphaherpesvirus, in porcine
nasal mucosal explants. With this novel in vitro system, it
was seen that PRV spread horizontally as well as vertically
in a plaque-wise manner in the epithelium, and that PRV-
induced plaques penetrated the BM barrier between 12 and
24 h p.i. (Glorieux et al., 2007). Importantly, these
observations were consistent with previous in vivo
observations of PRV replication (Pol et al., 1989). In the
present study, we studied the replication and invasion
strategies of EHV-1, a respiratory alphaherpesvirus in
horses of paramount economic importance, in a recently
established equine respiratory mucosa explant model
(Vandekerckhove et al., 2009). Briefly, EHV-1-induced
plaques were present in the epithelium starting from 24 h
p.i. and showed an increase in plaque latitude over time. In
striking contrast to what was observed for PRV, the spread
of EHV-1-induced plaques was solely lateral. This lateral
spread in the epithelium was clearly more pronounced for
some EHV-1 isolates, but no correlation was found with
the recently identified SNP in the DNA polymerase of the
virus associated with neurovirulent potential (Nugent et al.,
2006). In addition, by using the different recombinant
viruses Ab4 and NY03 harbouring the single D/N point
mutation, we observed that there was a difference in
number of plaques between these two viruses independent
of the D/N variant, which indicates that other virus
characteristics beyond ORF30 are important for virus
replication in the upper respiratory tract. This is in line
with what has been observed in many other studies (Lunn
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Fig. 5. Replication characteristics of strains Ab4 and NY03 and
their recombinant viruses. Equine respiratory mucosal explants
were inoculated with the N752/D752 recombinant viruses of strains
Ab4 (reference neurovirulent strain) and NY03 (reference non-
neurovirulent strain). At 0, 24 and 48 h p.i., explants were collected
and analysed. Empty bars, 24 h p.i.; filled bars, 48 h p.i. Data
shown represent means+SD of triplicate independent experi-
ments. Data carrying a different letter (a or b) are significantly
different from one another. m, Recombinant mutant virus; r,
recombinant revertant virus. (a) Number of plaques in epithelium
of nasal explants in 100 consecutive sections. (b) Total amount of
individual EHV-1-infected cells counted below the BM for every
strain at 48 h p.i. Every tenth section of a serially sectioned block of
tissue was collected and 100 sections were counted in total.
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et al., 2009). As plaques never crossed the BM at any time
point p.i., this implies that the BM functions as an absolute
barrier. Remarkably, however, single EHV-1-infected cells
were observed below the BM in the vicinity of virus-
induced plaques, although destruction of the BM by EHV-
1-induced plaques was never observed. Hence, these results
suggest that closely related alphaherpesviruses can use very
different ways of crossing the BM barrier and invading the
respiratory mucosa. Whereas it was previously shown that
the alphaherpesvirus PRV crosses the BM in an aggressive,
plaque-wise manner (Glorieux et al., 2007), we showed in
the present study that EHV-1 penetrates the deeper tissues
of the respiratory tract in a more discrete manner, using
migrating individual cells as Trojan horses.
When evaluating the invasion mechanisms of different
EHV-1 isolates more thoroughly, differences were observed
depending on the EHV-1 isolate used. An important
finding was the absence of single EHV-1-infected cells
below the BM barrier at 24 h p.i. for all non-neurovirulent
EHV-1 isolates carrying the N752 genotype in their DNA
polymerase when compared with neurovirulent, D752
isolates. What the underlying mechanism is for this faster
breakthrough through the BM barrier of neurovirulent
isolates remains to be elucidated, but we can state that (i)
the D/N752 SNP is important for this phenomenon and (ii)
the time-dependent difference in spread through the BM is
not an artefact in our system, as similar observations have
been made in vivo (Gryspeerdt et al., 2010). Indeed, single
EHV-1-infected cells below the BM were seen starting from
1 day p.i. for 03P37, a neurovirulent D752 isolate, whereas
for the non-neurovirulent N752 isolate 97P70, single
infected cells were observed as early as 2 days p.i. in this
in vivo experiment (Gryspeerdt et al., 2010). In our nasal
explant system, we observed no differences in cell tropism
between D752 and N752 isolates, and EHV-1-infected cells
were equally identified as CD5+ T lymphocytes and
CD172a+ CML. One Belgian isolate used in this study,
the neurovirulent 03P37, was a clear exception with
significantly more infected CML than CD5+ T lymphocytes.
As 03P37 was the most recently isolated strain used in this
study (2003), a possible explanation for this observation
could be that the leukocyte tropism of circulating EHV-1
isolates changes over time. To evaluate this hypothesis, we
studied the replication kinetics of recent Belgian D752 and
N752 isolates from 2009. For these recent EHV-1 isolates,
CML and CD5+ T lymphocytes were equally infected,
indicating that the leukocyte tropism had not changed over
time (data not shown). These results do not indicate that
recent EHV-1 strains evolve to another leukocyte tropism
and, as a result, we have as yet no explanation for the
unusual leukocyte tropism of the Belgian isolate 03P37.
Another interesting finding was a twofold higher infec-
tion of CD4+ T lymphocytes compared with CD8+ T
lymphocytes for all EHV-1 isolates examined in the present
study. CD4+ and CD8+ T lymphocytes are both crucial for
the establishment of an efficient cellular immune response.
CD4+ T lymphocytes assist other leukocytes in processes
such as maturation of B cells and activation of CD8+ T
lymphocytes and macrophages. In association with MHC
class I molecules, CD8+ T lymphocytes recognize and
destroy virus-infected cells. Cellular immunity is most
important in controlling an EHV-1 infection as neutral-
izing antibodies have been shown not to be fully protect-
ive (Kydd et al., 2006). Many factors indicate that T
lymphocytes play an important role in the clearance of
EHV-1 from the horse: (i) EHV-1 becomes intracellular
within hours p.i. and (ii) CD8+ T lymphocytes increase in
the blood and lungs after infection (Kydd et al., 2006).
Therefore, it is not surprising that EHV-1 preferentially
infects T lymphocytes, as this could allow the virus to
persist in its host for a longer period of time before being
eliminated.
In general, our findings in the equine nasal mucosal
explant system indicated that N752 strains are more prone
to replicate in epithelial cells, whilst D752 strains are
superior at infecting immune cells. This was shown by the
greater number of plaques in the epithelium upon infection
with N752 strains and their slower invasion kinetics to the
Table 3. Percentage of marker-positive EHV-1-infected individual cells for different EHV-1 strains and their recombinant viruses
Rev, Revertant; Mut, strain with the ORF30 mutation.
SNP/isolate Percentage of marker-positive EHV-1-infected individual cells in 20 cryosections per cell marker
24 h p.i. 48 h p.i.
CD172a+ CD5+ CD4+ CD8+ IgM+ CD172a+ CD5+ CD4+ CD8+ IgM+
D752
Ab4 84.4±3.9 15.6±3.9 0.0±0.0 10.8±10.4 0.0±0.0 29±0.9 39.9±1.3 35.3±9.1 18.1±11 0.0±0.0
Rev Ab4 79.3±6.9 4.8±8.3 0.0±0.0 0.0±0.0 0.0±0.0 35.5±19.8 31.9±13.8 37.1±11.1 37.6±14.6 0.3±0.3
Mut NY03 76.7±25.2 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 34.7±7.3 30.8±1.8 30.8±7.7 16.1±2.9 0.8±0.3
N752
NY03 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 25.3±6 34.9±2.2 31.8±8.7 20.4±1.8 1.7±0.6
Rev NY03 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 33.5±1.9 36.3±5.9 30.5±7.6 17.2±4.9 2.2±1.4
Mut Ab4 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 37.6±11.3 35±15.3 34±3.6 22.7±6.5 0.0±0.0
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connective tissue below the BM via infected immune cells.
D752 strains, in contrast, had a lower number of epithelial
plaques, but crossed the BM barrier earlier and with a
significantly greater number of infected immune cells.
Indeed, we observed that isolates with the D752 genotype
had significantly more single EHV-1-infected cells below
the BM than isolates with the N752 genotype, at 48 h p.i.
This is in agreement with several other studies, showing a
more robust replication of neurovirulent D752 isolates, as
shown by a higher level of viraemia of infected cells in the
blood (Allen & Breathnach, 2006; Goodman et al., 2006,
2007; Allen, 2008; Van de Walle et al., 2009).
To date, the mouse model is used as a valid in vivomodel for
studying virological and histological aspects of EHV-1-
induced disease in the horse (Walker et al., 1999). A big
concern, however, is the heterologous nature of this animal
model, which can make it difficult to make valid compari-
sons and extrapolations to the natural host of the virus, the
horse (Walker et al., 1999). Our in vitro model is a good
representation of the in vivo situation in the natural host, as
the results obtained in our study were virtually identical to
those obtained in a recent in vivo pathogenesis study in
horses by Gryspeerdt et al. (2010). Moreover, differences in
invasion kinetics and infection rates between neurovirulent
and non-neurovirulent EHV-1 isolates were identified,
indicating that our in vitro respiratory mucosal explant
system is a valuable alternative to provide novel information
in addition to the currently existing EHV-1 models.
In conclusion, the equine respiratory explant system can be
used for studying the early pathogenesis of EHV-1 strains
and deletion mutants with known neurovirulence, for
testing the potential of various vaccines and for investi-
gating the efficacy of antiviral drugs on EHV-1 infection at
the primary site of replication, the upper respiratory tract.
METHODS
Donor horses. Material from slaughter horses was used to obtain
nasal explants. All horses were between 4 and 7 years old, based on
inspection of the dental incisive architecture (Muylle et al., 1996), and
were inspected for nasal/ocular discharge and lung pathology. A
complement-dependent seroneutralization test was performed on the
serum of all horses and EHV-specific antibody titres ranged between 4
and 64.
Cultivation of nasal explants. The cultivation of nasal explants was
performed exactly as described previously (Vandekerckhove et al.,
2009). In brief, immediately after slaughter, the head was removed from
the carcass and sawn longitudinally into two equal sections. Tissue
from the deep intranasal part of the septum and the nasopharynx was
collected. The tissue was transported on ice in PBS, supplemented with
1 mg gentamicin (Gibco) ml21, 1 mg streptomycin (Certa) ml21,
1000 U penicillin (Continental Pharma) ml21, 1 mg kanamycin
(Sigma) ml21 and 5 mg Fungizone ml21, to the laboratory. Mucosal
explants were stripped from the surface of the different tissues by use of
surgical blades (Swann-Morton). The stripped mucosa of each tissue
was divided into equal explants of 25 mm2 and placed epithelium
upwards on fine-meshed gauze for culture at the air–liquid interface.
Only a thin film of serum-free medium [50% RPMI/50% Dulbecco’s
modified Eagle’s medium; Gibco) supplemented with 0.3 mg glu-
tamine (BHD Biochemical) ml21, 1 mg gentamicin ml21, 0.1 mg
streptomycin ml21 and 100 U penicillin ml21] covered the explants,
thereby mimicking the air–liquid interface found in the respiratory
tract of the living animal. Explants were maintained at 37 uC in an
atmosphere containing 5% CO2.
Viruses. Different Belgian EHV-1 strains were included in this study
and were genotyped in the ORF30 region by the Animal Health Trust,
UK (Nugent et al., 2006). The isolates 94P247 and 97P70 were
isolated from the lungs of aborted fetuses in 1994 and 1997,
respectively, and typed as non-neurovirulent. The isolates 97P82,
99P136 and 03P37 were isolated from the peripheral blood mono-
nuclear cells of paralytic horses in 1997, 1999 and 2003, respectively,
and typed as neurovirulent. Parental Ab4 (reference neurovirulent
strain, containing D752 in ORF30), N752 mutant (D752AN mutation)
and D752 revertant (N752AD substitution) recombinant viruses, and
parental NY03 (reference non-neurovirulent strain, containing N752),
D752 mutant (N752AD mutation) and N752 revertant (D752AN
substitution) recombinant viruses, were also included in this study
(Goodman et al., 2007; Van de Walle et al., 2009).
All virus stocks used for inoculation were at the sixth passage, after
two passages in rabbit kidney (RK13) cells and four subsequent
passages in equine embryonic lung cells. In addition, all virus stocks
used for inoculation were sequenced in their ORF30 region to
confirm the correct genotype (data not shown).
Inoculation of nasal explants. All explants were inoculated after
24 h culture. Inoculation took place by immersion of the explant in
1 ml inoculum, containing 106.5 50% tissue culture infectious doses
of EHV-1 for 1 h at 37 uC and 5% CO2. After incubation, the
explants were washed twice with warm medium and transferred back
to their gauze. At several time points p.i., explants were collected,
embedded in methylcellulose medium (Methocel MC; Sigma-
Aldrich) and frozen at 270 uC.
In the first experiment, six individual slaughter horses were divided
into two groups. Nasal and nasopharyngeal explants of the three
individual horses from the first group were inoculated with the D752
isolate 03P37, whilst nasal and nasopharyngeal explants of the other
three horses were inoculated with the N752 isolate 97P70. For each
animal, one explant was examined at each collected time point (0, 12,
24, 36, 48 and 72 h p.i.).
In the second and third experiment, the nasal explants of three horses
were collected. For each horse, several explants were made and
inoculated with different EHV-1 isolates (94P247, 97P70, 97P82,
99P136, 03P37, parental Ab4, mutant Ab4, revertant Ab4, parental
NY03, mutant NY03 and revertant NY03) and collected at different
time points (0, 24 and 48 h p.i.).
Plaque analysis and penetration of virus plaques through the
BM. At 0, 12, 24, 36, 48 and 72 h p.i., 100 consecutive cryosections of
16 mm were made from the frozen explants and the cryosections were
fixed in 100% methanol for 20 min at 220 uC. Subsequently, the BM
of the tissues was stained with monoclonal mouse anti-collagen VII
antibodies (Sigma-Aldrich), followed by secondary Texas red-labelled
goat anti-mouse antibodies (Molecular Probes). In a second step, viral
proteins were stained by incubation with biotinylated equine polyclonal
anti-EHV-1 IgG (van derMeulen et al., 2003), followed by streptavidin–
fluorescein isothiocyanate (FITC; Molecular Probes). Antibodies were
incubated for 1 h at 37 uC and 5% CO2. Finally, the cryosections were
washed three times in PBS and mounted with glycerine/1,4-diazabicy-
clo[2.2.2]octane (DABCO; Janssen Chimica). All stainings were analysed
with a confocal laser-scanning microscope (TCS SP2 Laser Scanning
Spectral Confocal System; Leica Microsystems) using Leica confocal
software. To analyse the replication characteristics of several EHV-1
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isolates reproducibly, we used a system set up by Glorieux et al. (2009).
Briefly, penetration of the virus through the BMwas inspected and virus
plaque latitudes and plaque volumes were measured in 100 consecutive
cryosections using the freely available ImageJ version 1.28 software
(http://rsb.info.nih.gov/ij/docs/intro.html). For each cryosection, a
stack of z-series was made. A z-series was defined as a series of images
in the axis perpendicular to the image plane, so in the depth of the
tissue. Hereafter, voxels (defined as a volume element that represents a
value in three-dimensional space) positive for FITC fluorescence were
counted. To cover an entire plaque, different cryosections were
combined. Finally, the total number of voxels was multiplied by voxel
volume to obtain plaque volume. Plaque latitude was measured by
means of the line tool in ImageJ.
Quantification and characterization of individual infected cells.
Immunofluorescent double stainings were used to quantify and
characterize individual infected cells below the BM. At different time
points p.i., 100 cryosections of 16 mm were made and fixed in 100%
methanol for 20 min at 220 uC. Every tenth section of a serially
sectioned block of tissue was collected. Twenty cryosections were
stained for each cell-surface marker separately. In the first step, the
monoclonal antibodies HT23A, HB61A, 73/6.9.1, DH59B and 1.9/3.2
(VMRD) were used as markers for CD5+ T lymphocytes (pan-equine
T-lymphocyte marker), CD4+ T lymphocytes (helper T lymphocytes),
CD8+ T lymphocytes (cytotoxic T lymphocytes), CD172a+ cells from
the monocyte lineage (CML) or B lymphocytes (IgM+), respectively. As
controls, (i) stainings were performed on uninfected tissue and (ii)
corresponding isotype control antibodies were included. Subsequently,
cryosections were incubated with secondary Texas red-labelled goat
anti-mouse antibodies. In the second step, all cryosections were stained
for viral proteins by incubation of biotinylated equine polyclonal anti-
EHV-1 IgG (van der Meulen et al., 2003), followed by streptavidin–
FITC. In general, antibodies were incubated for 1 h at 37 uC and 5%
CO2. Finally, cryosections were washed three times in PBS and
mounted with glycerine/DABCO. The number of individual infected
cells below the BM, as well as their identity, was determined by confocal
laser-scanning microscopy. Therefore, two defined regions of interest
were taken into account in the cryosections: one region with a plaque
situated in the epithelium and one region without a plaque in the
epithelium (Fig. 2a). These regions were subsequently subdivided into
three further regions: A, B and C for the regions below a plaque and D,
E and F for the regions without a plaque.
Statistical analysis. Data were analysed by a mixed model with the
horse as the random effect and strain, time and their interaction as
categorical effects (SAS version 9.2; SAS Corp.). F-tests were
performed at the 5% global significance level. P values for pairwise
comparisons between the strains were adjusted for multiple
comparisons using Tukey’s method. The data were presented as
means±SD.
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